435 related articles for article (PubMed ID: 22119737)
1. Guidelines for the diagnosis and management of Catecholaminergic Polymorphic Ventricular Tachycardia.
Pflaumer A; Davis AM
Heart Lung Circ; 2012 Feb; 21(2):96-100. PubMed ID: 22119737
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature.
Pott C; Dechering DG; Reinke F; Muszynski A; Zellerhoff S; Bittner A; Köbe J; Wasmer K; Schulze-Bahr E; Mönnig G; Kotthoff S; Eckardt L
Europace; 2011 Jun; 13(6):897-901. PubMed ID: 21292648
[TBL] [Abstract][Full Text] [Related]
3. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.
Khoury A; Marai I; Suleiman M; Blich M; Lorber A; Gepstein L; Boulos M
Heart Rhythm; 2013 Nov; 10(11):1671-5. PubMed ID: 23954267
[TBL] [Abstract][Full Text] [Related]
4. Description of a novel RyR2 mutation in a juvenile patient with symptomatic catecholaminergic polymorphic ventricular tachycardia in sleep and during exercise: a case report.
Seidlmayer LK; Riediger F; Pagonas N; Nordbeck P; Ritter O; Sasko B
J Med Case Rep; 2018 Oct; 12(1):298. PubMed ID: 30296944
[TBL] [Abstract][Full Text] [Related]
5. Deadly proposal: a case of catecholaminergic polymorphic ventricular tachycardia.
Heiner JD; Bullard-Berent JH; Inbar S
Pediatr Emerg Care; 2011 Nov; 27(11):1065-8. PubMed ID: 22068070
[TBL] [Abstract][Full Text] [Related]
6. Mechanism underlying catecholaminergic polymorphic ventricular tachycardia and approaches to therapy.
Watanabe H; Knollmann BC
J Electrocardiol; 2011; 44(6):650-5. PubMed ID: 21872879
[TBL] [Abstract][Full Text] [Related]
7. Catecholaminergic polymorphic ventricular tachycardia.
Liu N; Ruan Y; Priori SG
Prog Cardiovasc Dis; 2008; 51(1):23-30. PubMed ID: 18634915
[TBL] [Abstract][Full Text] [Related]
8. Catecholaminergic polymorphic ventricular tachycardia.
Liu N; Colombi B; Raytcheva-Buono EV; Bloise R; Priori SG
Herz; 2007 May; 32(3):212-7. PubMed ID: 17497254
[TBL] [Abstract][Full Text] [Related]
9. Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia.
Sy RW; Gollob MH; Klein GJ; Yee R; Skanes AC; Gula LJ; Leong-Sit P; Gow RM; Green MS; Birnie DH; Krahn AD
Heart Rhythm; 2011 Jun; 8(6):864-71. PubMed ID: 21315846
[TBL] [Abstract][Full Text] [Related]
10. Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives.
van der Werf C; Nederend I; Hofman N; van Geloven N; Ebink C; Frohn-Mulder IM; Alings AM; Bosker HA; Bracke FA; van den Heuvel F; Waalewijn RA; Bikker H; van Tintelen JP; Bhuiyan ZA; van den Berg MP; Wilde AA
Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):748-56. PubMed ID: 22787013
[TBL] [Abstract][Full Text] [Related]
11. Co-Phenotype of Left Ventricular Non-Compaction Cardiomyopathy and Atypical Catecholaminergic Polymorphic Ventricular Tachycardia in Association With R169Q, a Ryanodine Receptor Type 2 Missense Mutation.
Nozaki Y; Kato Y; Uike K; Yamamura K; Kikuchi M; Yasuda M; Ohno S; Horie M; Murayama T; Kurebayashi N; Horigome H
Circ J; 2020 Jan; 84(2):226-234. PubMed ID: 31875585
[TBL] [Abstract][Full Text] [Related]
12. [Catecholaminergic polymorphic ventricular tachycardia].
Leren IS; Haugaa KH; Edvardsen T; Anfinsen OG; Kongsgård E; Berge KE; Leren TP; Amlie JP
Tidsskr Nor Laegeforen; 2010 Jan; 130(2):139-42. PubMed ID: 20125202
[TBL] [Abstract][Full Text] [Related]
13. Clinical and molecular characterization of a cardiac ryanodine receptor founder mutation causing catecholaminergic polymorphic ventricular tachycardia.
Wangüemert F; Bosch Calero C; Pérez C; Campuzano O; Beltran-Alvarez P; Scornik FS; Iglesias A; Berne P; Allegue C; Ruiz Hernandez PM; Brugada J; Pérez GJ; Brugada R
Heart Rhythm; 2015 Jul; 12(7):1636-43. PubMed ID: 25814417
[TBL] [Abstract][Full Text] [Related]
14. High prevalence of exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia mutation-positive family members diagnosed by cascade genetic screening.
Haugaa KH; Leren IS; Berge KE; Bathen J; Loennechen JP; Anfinsen OG; Früh A; Edvardsen T; Kongsgård E; Leren TP; Amlie JP
Europace; 2010 Mar; 12(3):417-23. PubMed ID: 20106799
[TBL] [Abstract][Full Text] [Related]
15. Catecholaminergic polymorphic ventricular tachycardia in a child: a case report.
Garabedian L; Verryckt A; Panzer J; De Wolf D
Acta Paediatr; 2008 Jan; 97(1):127-9. PubMed ID: 18052993
[TBL] [Abstract][Full Text] [Related]
16. Advances in the diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia.
Roston TM; Cunningham TC; Sanatani S
Cardiol Young; 2017 Jan; 27(S1):S49-S56. PubMed ID: 28084961
[TBL] [Abstract][Full Text] [Related]
17. Catecholaminergic polymorphic ventricular tachycardia.
Leenhardt A; Denjoy I; Guicheney P
Circ Arrhythm Electrophysiol; 2012 Oct; 5(5):1044-52. PubMed ID: 23022705
[No Abstract] [Full Text] [Related]
18. Clinical characteristics and mutational analysis of the RyR2 gene in seven Czech families with catecholaminergic polymorphic ventricular tachycardia.
Andrsova I; Valaskova I; Kubus P; Vit P; Gaillyova R; Kadlecova J; Manouskova L; Novotny T
Pacing Clin Electrophysiol; 2012 Jul; 35(7):798-803. PubMed ID: 22519458
[TBL] [Abstract][Full Text] [Related]
19. Left cardiac sympathetic denervation for the management of life-threatening ventricular tachyarrhythmias in young patients with catecholaminergic polymorphic ventricular tachycardia and long QT syndrome.
Schneider HE; Steinmetz M; Krause U; Kriebel T; Ruschewski W; Paul T
Clin Res Cardiol; 2013 Jan; 102(1):33-42. PubMed ID: 22821214
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
